Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIB305 in Advanced Solid Tumors
NCT07222969Phase 2Recruiting
- Sponsor
- Vibrant Sciences
- Start
- Jan 2026
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
A Phase 2 trial of VIB305 in solid tumor (advanced stage), sponsored by Vibrant Sciences. Started Jan 2026; status: recruiting.
02
Drugs
VIB305
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07222969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07222969.